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George Buchanan,1 Elliott Vichinsky,2 Lakshmanan Krishnamurti,3 Shalini Shenoy4Over 70,000 people live with sickle cell disease (SCD) in the United States and multitudes worldwide. About
2000 afflicted babies are born in this country each year. In African countries such as Nigeria, over 100,000
babies are born with the disease each year. Great strides have been made in the conservative management of
SCD. However, the medical and psychosocial cost of supporting patients with this chronic illness is enormous
and spans a lifetime. Hematopoietic stem cell transplantation (HSCT) can abrogate SCD manifestations, and
is the best option for cure today. Yet, this treatment modality is underutilized as less than 500 transplants are
reported in the Center for International Blood and Marrow Transplant Research (CIBMTR) database be-
cause of its significant risk of morbidity and mortality. There is growing understanding of the pathophysiology
of the disease, and this, coupled with advances in transplantation and new approaches to therapy, continue
to improve care of patients with SCD both in children and during adulthood. Continuing investigation seeks
to predict the course of the disease and to determine timing and modality of therapy in order to optimize
outcomes.
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CHRONIC ORGAN DAMAGE IN SICKLE
CELL DISEASE
Patients with sickle cell disease (SCD) have an
abnormal hemoglobin that polymerizes under physio-
logic conditions, leading to the formation of distorted
and rigid red blood cells. This, in turn, causes hemoly-
sis and obstruction of blood flow in the microcircula-
tion, with resultant tissue ischemia and necrosis. Pain
and organ injury are the sequelae.
The organs damaged by the abnormal erythrocytes
vary according to patient age, the specific sickle cell
genotype, other gene polymorphisms, and environ-
mental phenomena. Organ damage can be acute or
chronic, symptomatic or clinically silent, and episodic1University of Texas Southwestern at Dallas, Texas;
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complications that characterize SCD as a severe clini-
cal entity include vaso-occlusive or pain crisis, acute
chest syndrome, stroke, and priapism. Because of the
clinical heterogeneity of SCD, there has been a great
deal of interest in predicting at the earliest possible
age which patients will be most severely affected. If
such high-risk patients could be identified, early inter-
vention might be prescribed to avert organ injury. In
2000, Miller and colleagues [1] reported for the Coop-
erative Study of Sickle Cell Disease that several clinical
and laboratory markers during the first 2 years of life
predict a severe clinical course (characterized by early
death or recurrent pain crisis or chest syndrome) dur-
ing the ensuing 10 years. However, a similar study of
the Dallas Newborn Cohort reported by Quinn and
colleagues [2] in 2008 refuted this finding. Thus, at
present, there are no reliably validated measures in
the young child that can predict long-term outcomes.
Although the acute events just described cause
much morbidity during childhood as well as in adults,
the toll of chronic sickling and vascular injury as well as
ongoing hemolysis also promotes insidious, silent,
clinically inapparent, but progressive organ damage.
Such injury involves the lungs, heart, brain, kidneys,
bones, and other organs. The damage may not become
manifest until early or midadulthood, often after
a seemingly benign clinical course during the child-
hood years. Some, if not much, of this organ dysfunc-
tion, results primarily from the chronic anemia or
Biol Blood Marrow Transplant 16:S64-S67, 2010 S65Severe Sickle Cell Diseaseperhapsmore specifically from intravascular hemolysis.
Specific complications include pulmonary hyperten-
sion, osteonecrosis, chronic renal disease, and cogni-
tive dysfunction. Attention is currently being given
by investigators and clinicians to this progressive or-
gan damage, for it is a major cause of morbidity and
premature death in adult patients with SCD. Many
such patients seem to do well during childhood, but
are vulnerable to developing irreversible organ damage
because of chronic hemolytic anemia and/or vascular
occlusion in young adulthood. These patients are
now increasingly considered candidates for the same
disease-modifying interventions as those children and
adults with more clinically apparent recurrent vaso-
occlusive events.
At this time, the major treatments that can truly
prevent or lesson the burden of recurrent pain and
organ damage are hydroxyurea, chronic blood transfu-
sions, and hematopoietic stem cell transplantation
(HSCT). The real question is which of these 3
approaches (as well as novel interventions yet to be
developed or perfected) is most appropriate for an
individual patient. An equally important question is
when such intervention should be initiated to derive
optimal benefit. Because each of the 3 primary treat-
ment modalities has substantial adverse effects, the
careful assessment of the risk-benefit ratio is crucial.
Some clinical trials are ongoing, and many others
need to be designed and performed to generate conclu-
sive answers to this vexing question.MEDICAL MANAGEMENTOF SCD
Improved therapy has dramatically changed the
prognosis of SCD. Once a fatal pediatric illness, it is
now a chronic adult disease characterized by poor
quality of life with end-organ failure and acute inter-
mittent medical emergencies. Identification of high-
risk patients, preventative therapies, and optimal
management of complications can minimize the
morbidity of SCD and alter its progressive decline.
Annual screening with transcranial doppler enables
selective chronic transfusions to be implemented that
successfully prevent central nervous system (CNS)
injury. Early detection of asthma, pulmonary hyperten-
sion, and hypoxia is important for improved outcomes
[3,4]. Acute chest syndrome, the most common cause
ofmortality, canoftenbepreventedorminimized.Renal
failure may be prevented by early treatment of protein-
uria with ACE inhibitors. Avascular necrosis of the hip
may affect up to 40% of patients; early detection and
treatment with decompression coring procedures and
aggressive physical therapy may prevent or slow pro-
gression to major surgery. Priapism, a morbid, often
underreported complication requiring surgery, may be
prevented by alpha/beta adrenergic agonists, gonado-tropin releasing hormone, and phosphodiesterase
inhibitors. Pain management in SCD remains inade-
quate, but may be improved by the day hospital model,
avoidance of hyperanalgesia syndrome, and effective
use of opioids. Nutritional deficiencies are common
and correctable, and can improve bone density and
general health.
Transfusion therapy has seen major advances, and
is used in over 90% of patients by adulthood. Pheno-
typically matched units, access to cytopheresis and
availability of oral iron chelators have resulted in lower
alloimmunization rates and decreased iron overload.
Hydroxyurea has globally altered the morbidity of
SCD. New hemoglobin F modulating drugs such as
decitabine and short-chain fatty acids may further
improve outcomes. Emerging therapies resulting
from an expanded understanding of the pathophysiol-
ogy of SCD are promising, and have entered clinical
trials; these include statins, pan-selectin inhibitors,
anticoagulants, glutamine, and nitric oxide modifying
therapies. Although gene therapy has entered Phase I
trials, stem cell transplant remains the only available
cure for this disease.STEM CELLTRANSPLANTATION FOR SCD
HSCT is currently the only curative therapy for
SCD. Children with HLA matched sibling donors
(normal or with sickle trait) have excellent outcomes
with HSCT, with 85% disease free survival (DFS)
and 97% overall survival (OS) [5-7]. The majority of
SCD transplants reported worldwide to date include
matched sibling donor transplants in children. Unre-
lated donor transplantation has met with less success
in SCD as has HSCT in older recipients, including
transplantation in young adulthood. Although the
‘‘ideal’’ time to transplant is at a young age, prior to
the development of irreversible vasculopathy, there
are several reasons that have precluded using HSCT
as curative therapy and an accepted standard of care
for SCD. This is true even when the clinical history
predicts a severe disease course with early fatality or
significant morbidity, as in the case of multiple overt
strokes. Eleven percent of patients develop a stroke
by 18 years of age, and 20% of this group continue
with recurrent strokes despite transfusion therapy,
resulting in 5% mortality in the second decade [8,9].
From the donor perspective, obstacles to HSCT
include the rarity of availability of aHLA-matched sib-
ling donor (\18%) and the lowered incidence of find-
ing a suitably matched unrelated donor (MUD) or
umbilical cord product in this minority population
[10,11]. From the recipient perspective, transplant
outcomes worsen with age and presumably advanced
disease [12]. HSCT is best performed in childhood
prior to established disease sequelae to optimize
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way to predict which SCD patient would benefit early
from HSCT prior to the development of major com-
plications still remains a dilemma. Recent advances
in conservative therapy have provided significant early
benefit in many patients with SCD leaving a smaller
number with clearly progressive disease in childhood.
Concern for transplant-related complications such as
conditioning-related organ dysfunction, treatment-
related mortality (TRM), infection, graft-versus-host
disease (GVHD), and graft rejection demand that
HSCT be optimized to ensure the best possible out-
comes with minimal mortality. This is also true for
late complications of transplant such as gonadal fail-
ure, second malignancies, and neurodevelopmental
issues, especially for those patients transplanted at
a young age. Advances in the field of HSCT related
to high-resolution HLA typing and choice of stem
cell sources, less toxic conditioning strategies, newer
immune suppression medications, facilitated immune
reconstitution, and improved supportive care have
helped tomakeHSCT amore viable option in nonma-
lignant disorders including SCD [13-17]. The balance
between the acceptability of HSCT as a cure for SCD
and complications associated with the HSCT versus
from the primary disease remains a question of ethical
importance and an educational journey for families
caring for patients with SCD [18,19].TRAJECTORYOF DISEASE PROGRESSION
IN ADULTHOOD: THE CASE FOR NOVEL
INTERVENTIONS
The outcomes of children with SCDhave improved
dramatically as described earlier because of better com-
prehensive care, pneumococcal prophylaxis, in addition
to transfusion therapy and hydroxyurea. Currently,
.90%of newborns with SCD can expect to live beyond
their 20th birthday [20]. However, this optimistic
outlook begins to unravel soon after. There is a rapid
progression in organ damage andmorbidity with amor-
tality rate of 5.8% to 20% in the first 10 years after tran-
sition to adult care [21,22]. Disease progression is
marked by multiple organ toxicities. Starting in late
adolescence, there is an increasing incidence of pulmo-
nary hypertension in patients with SCD, with 40% of
patients affected by this condition by 40 years of age
[23]. This complication is associated with a 2-year mor-
tality of 50%. Pulmonary function tests are abnormal in
90% of adults and lung disease is predominantly (74%)
restrictive in nature [24]. Renal insufficiency is present
in 21% and albuminuria in 68% of adults [25]. Bone
mineral density is reduced in 74% adults [26]. By the
fifth decade of life, 50% of the patients have irreversible
organ damage of at least 1 organ [20]. These complica-
tions are the cause for prematuremortality, with a meanage of death at merely 38 years [27]. In addition, there is
substantial disease-related morbidity and poor health-
related quality of life resulting in impaired societal func-
tioning. As a result, fewer than 20% of patients with
SCD gain and retain employment [28]. Because chil-
dren with SCD have excellent outcomes with appropri-
ate intervention and comprehensive care, interventions
such asHSCT remain limited in consideration/applica-
tion largely because of the associated risks described
previously. However, the risk of interventions such as
HSCT, chronic transfusion therapy, and hydroxyurea
has to be balanced between excellent early disease out-
comes and disease course in the later years. An emerging
understanding of the severity and progression of disease
in adults can alter the risk versus benefit paradigm of cu-
rative interventions such as HSCT. There is increasing
interest among adult SCDpatients and hematologists in
clinical trials ofHSCTand other treatment options that
may provide benefit to the later complications of the
disease. For HSCT, TRM, GVHD, and late sequelae
such as infertility are still major barriers to adequately
exploring this intervention. However, progress in trans-
plant research designed to improve outcomesmaymake
HSCT a viable intervention in patients with severe
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